Cigna PBM Express Scripts Excludes Humira in Favor of Biosimilars
Cigna PBM Express Scripts Takes Action
Cigna PBM Express Scripts has announced a significant decision to remove Humira from numerous formularies. As a potent rheumatoid arthritis medication, AbbVie’s Humira has been a mainstay for many patients. However, in a bid to lower costs, Cigna is leaning towards introducing cheaper biosimilar versions of the drug by 2025.
The Financial Implications
This decision may lead to profound changes in the pharmaceutical landscape, impacting both patients and drug manufacturers. Lowering costs is a primary focus for healthcare providers, and this strategy might increase the adoption of biosimilars, further shifting market dynamics.
Industry Repercussions
As biosimilars gain traction, the competition may spur innovation and drive down prices across the sector. Cigna’s move reflects a growing trend among pharmaceutical benefits managers to enhance cost-efficiency.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.